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Abstract
Persistent high-risk human papillomavirus (HR-HPV) infection is the strongest risk factor for
high-grade cervical precancer. We performed a systematic review and meta-analysis of HPV
persistence patterns worldwide. Medline and ISI Web of Science were searched through January
1, 2010 for articles estimating HPV persistence or duration of detection. Descriptive and meta-
regression techniques were used to summarize variability and the influence of study definitions
and characteristics on duration and persistence of cervical HPV infections in women. Among 86
studies providing data on over 100,000 women, 73% defined persistence as HPV positivity at a
minimum of two time points. Persistence varied notably across studies and was largely mediated
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by study region and HPV type, with HPV-16, 31, 33 and 52 being most persistent. Weighted
median duration of any-HPV detection was 9.8 months. HR-HPV (9.3 months) persisted longer
than low-risk HPV (8.4 months), and HPV-16 (12.4 months) persisted longer than HPV-18 (9.8
months). Among populations of HPV positive women with normal cytology, the median duration
of any-HPV detection was 11.5 and HR-HPV detection was10.9 months. In conclusion, we
estimated that approximately half of HPV infections persist past 6–12 months. Repeat HPV testing
at 12 month intervals could identify women at increased risk of high-grade cervical precancer due
to persistent HPV infections.
Keywords
human papillomavirus; HPV; duration; persistence; clearance; natural history; repeat testing;
literature review; screening; cervical cancer; meta-analysis
INTRODUCTION
Infection with high-risk human papillomavirus (HR-HPV) genotypes is considered
necessary for the development of invasive cervical cancer (ICC)1–4. Despite the high
prevalence of HR-HPV infections among women, the incidence of ICC is comparatively
low, which highlights the importance of factors that may mediate progression to invasive
cancer. Persistent HR-HPV infection has been consistently and strongly associated with
cervical intraepithelial neoplasia (CIN) of grades 2 and 35 and is considered essential for the
progression of cervical precancer to ICC6. The higher sensitivity of HPV testing but lower
specificity, as compared with cytology for the detection of CIN2–37–9, suggest that co-
testing with cytology and HPV could enhance accuracy in identifying women at high risk of
cervical precancer and cancer5, 10. Recent ASC/ASCCP/ASCP guidelines for cervical
cancer screening in women older than 30 years recommend that one option for women with
normal cytology and a positive HPV testing is rescreening in one year with Pap smear and
HPV co-testing11. Implementation of repeat HPV testing in screening requires a clinically
relevant definition of HPV persistence and a better understanding of HPV persistence
duration.
There has been wide variation in definitions of HPV persistence used in the literature. Given
that aspects of the definition of persistence, such as the frequency and length of testing
intervals, may affect the estimated risk of cervical precancer associated with HPV
persistence5, persistence and duration of HPV should be better understood to operationalize
inclusion of repeat testing into future cervical cancer screening programs and for use as an
endpoint in HPV vaccine trials and efficacy modeling. To date, there is no summary of the
literature that examines definitions and estimates of HPV persistence across studies. Thus,
we performed a systematic review and meta-analysis to determine the influence of HPV
persistence definitions and study characteristics on estimated duration of HPV infection and
proportion of women with persistently detectable HPV DNA over time.
METHODS
Eligibility and data abstraction
Studies published through January 1, 2010 were identified by searching ISI Web of Science,
MEDLINE via PubMed, and the reference lists from eligible articles and relevant review
articles, with no language restrictions. Only original peer-reviewed journal articles were
included. Broad search term categories included HPV (e.g. HPV, human papillomavirus)
and persistence (e.g. persistence, clearance, duration) (see online supplement for full set of
terms).
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To be included in this review, eligible articles had to present one or more measures of HPV
persistence over time, regardless of study design. The overall prevalence of cervical
abnormalities, as measured and defined by each study (generally atypical squamous cells of
undetermined significance (ASCUS) or greater), at baseline in the study population had to
be less than 15% to approximately reflect the characteristics of populations of average
risk12. However, population-based studies that did not explicitly state the prevalence of
cervical abnormalities were included. Only human immunodeficiency virus (HIV) negative
study populations were included; articles that did not state HIV serostatus were assumed to
be HIV negative and were included. Studies that tested for cervical or cervicovaginal HPV
infections using polymerase chain reaction (PCR) or Hybrid Capture (HC; QIAGEN
Gaithersburg, Inc.) DNA detection methods were included. We excluded serology-, male-
and low-risk HPV (LR-HPV)-only studies, post-treatment studies, studies with less than
three months of total study follow-up, and studies that included only buccal,
nasopharyngeal, anal, vulvar or labial specimens. All search results were independently
reviewed to ensure that no pertinent articles were omitted.
Abstracted persistence data included (i) proportion of HPV-positive (incident or prevalent)
women with persistent infections and the standard error or confidence interval, (ii) median
and/or mean duration of HPV infection, and (iii) HPV persistence estimates extracted from
Kaplan-Meier survival curves. Variables used to define persistence were abstracted, which
included HPV testing interval, number of HPV positive tests, minimum duration of HPV
infection to be considered persistent, whether persistence was based on detection of the
same HPV type at visit ‘v’ and ‘v+1’ (type-specific persistence) or detection of any HPV
type at consecutive visits (non-type-specific), and HPV type (e.g., HPV-16) or HPV
grouping (e.g., HR-HPV positivity)). Data were abstracted on population characteristics and
study methods, including geographical region, study design, sample size, population and
HPV detection method. All data were independently double-abstracted to ensure accuracy.
Study authors were contacted if clarification of published information on HPV persistence
was needed.
Selection of Persistence Estimates
Many articles that met the inclusion criteria were based on the same study population (28
articles from 11 populations). To maintain the independence of study results, the article from
a given study population was chosen that used the most sensitive detection method (e.g.,
PGMY09/11 over MY09/11, GP5+/6+ over GP5/6)13–15. If HPV methods were similar, we
chose the article with more women in the persistence analysis, or the most recent, if study
sample sizes did not vary. If multiple articles from the same study population could
contribute to separate analyses (e.g., persistence by baseline HPV status and persistence by
HPV type), all relevant articles were included.
Most articles (n=57) presented multiple estimates for the proportion persistent or median
duration of infection. A set of decision rules was applied to select one result for each meta-
regression or meta-regression stratum: (i) choose the HR-group result first, then any-HPV,
then single HR-HPV types based on worldwide HPV prevalence in ICC16: 16, 18, 33, 45,
31, 58, 52, 35; (ii) choose the type-specific result over the non-type-specific result; (iii)
choose the result with the greatest number of visits used to define persistence unless
substantially fewer (30%) women were tested at that visit; (iv) choose the result with mixed
incident and prevalent HPV infections first, then incident, then prevalent; (v) if results are
presented by age categories, choose the overall estimate first, then choose youngest to
oldest; (vi) if results are presented by HPV type variants, choose the estimate for all variants
combined or else the largest sample size; (vii) if results are presented by cytology method
(e.g. thin-prep, conventional), choose the overall estimate, then the largest sample size.
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The number and proportion of persistence estimates were calculated for each category of a
given study characteristic. If an article reported multiple results that fell into different
categories of study characteristics, the article was included in all relevant categories so
results could add to more than 100%. The median duration of HPV infection could not be
formally analyzed by meta-regression because most studies did not provide a measure of
random error. Instead, estimates of median HPV duration were graphed on a forest plot for
HPV groups and HPV types with at least three estimates of median duration. The pooled
duration for each HPV group and type was then calculated as the average, weighted by the
number of women that were included in each result. Plotting symbols were sized in
proportion to the number of women included in the calculation of median duration for each
study. Articles that presented Kaplan-Meier curves or reported the proportion persistent at
two or more time points were included in a figure to examine patterns of HPV persistence
within and across HPV groups. To examine the effect of age on HPV persistence within
study populations, any-HPV or else HR-HPV estimates were plotted by age. The mid-range
of each reported age category was used to plot persistence, where grayscale symbols
indicates the category of the reported mid-point. All figures were created using R version
2.10.1.
Statistical analyses
The proportion persistent was calculated in different ways in the literature: using either
women or infections as the unit of analysis, and including all women or only women with
infections in the denominator. To standardize the persistence results for inclusion in the
same analyses, the total number of women with an HPV infection at baseline (prevalent
persistence) and the total number of women who acquired an incident infection (incident
persistence) was used as the denominator to calculate the proportion persistent. If both
prevalent and incident infections were included in the persistence estimate, both were
included in the denominator. If a persistence result was stratified or limited to a subset of the
sample (e.g., women with a given HPV type), the number of women with an infection in that
particular stratum was used as the denominator. For studies that did not report a standard
error for the proportion persistent, it was calculated as the square root of (p*(1−p))/n, where
p was the observed proportion persistent and n was the sample size. In cases where the
proportion persistent was 0% or 100% and the standard error was undefined, the following
adjustment17 was made to calculate the standard error: the overall meta-regression model
was first fitted without study characteristics using all studies with defined standard errors.
Based on the summary estimate of 40% persistence at 6 months, the undefined standard
errors were then estimated by adding 0.4 to the number of women who persisted and 0.6 to
the number of women who did not persist (i.e. +0.4/+0.6 adjustment). If the standard error
was not reported and could not be calculated, the result was not included in meta-regression
analyses.
Random-effects meta-regression and stratification was used to formally compare differences
in proportion persistent estimates across study characteristic categories (i.e., difference
between estimates in each category compared to a common referent), with the among-study
variance estimated by restricted maximum likelihood18. Stratified summary estimates
allowed descriptive comparisons across individual categories of study characteristics (i.e.,
summary estimates and 95% confidence intervals for each category). Variation between
estimates was evaluated by comparing Cochran’s Q two-sided P-value with a 0.1
significance level19. The mean length of the testing interval multiplied by the number of
HPV testing intervals used to define persistence was included in models, centered at 6
months, as a means to control for the time over which persistence was measured. If the mean
testing interval was not reported, the interval specified in the study protocol or the minimum
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time required to meet the authors' definition of persistence was used. For these analyses, at
least three study estimates in each stratum were required. Studies were allowed to contribute
to more than one category to reduce the influence of the decision rules on the distribution of
study and population characteristics. When multiple results from the same study population
were included an indicator variable for that study population was included in the model to
account for the lack of independence. Methods and results for sensitivity analyses on
adjustment method and choosing rules are presented in an online supplement. Meta-
regression analysis was conducted in STATA version 11 (StataCorp, College Station, TX).
RESULTS
Descriptive results
Eligible studies—Of the 4,203 abstracts identified, 86 studies met the study inclusion
criteria and reported non-duplicate results. These studies provided estimates of HPV
persistence on over 100,000 women. Most studies were conducted in Europe (40%) and
North America (29%), with few from each of the other world regions (Central or South
America (20%), Asia (5%), Africa (3%) and Australia (1%)) (Table 1). Over half of the
results were among women with an average age of 30 years or older, although average age
was not reported in 14% of studies. Most studies (65%) were of populations where 100% of
women had normal cytology at baseline and were screening-based cohort studies that
employed PCR-based detection methods. MY09/11 alone or MY09/11 in combination with
other methods was the most frequently used HPV laboratory detection protocol (43%).
Definitions and characteristics of HPV persistence—HPV persistence was most
commonly defined as two or more HPV DNA positive time points (73%; Table 1), whereas
other definitions included a minimum of three positive tests, infection duration, and
persistent pairs (positive at any pair of visits, v and v+1). Consecutive HPV positive visits
were generally required for HPV persistence, but intervening HPV DNA negative visits
were allowed in 12 (14%) of the studies20–27. Minimum duration of HPV persistence,
defined as the shortest time period of HPV positivity for a woman to be considered
persistent, was 6 to <12 months for most studies (41%). The median time between HPV tests
(i.e. the testing interval) was 6 months, although there was a wide range of testing intervals,
from 1.328 to 117.629 months. Most studies reported type-specific HPV persistence (72%)
and persistence among HPV infections that were prevalent at baseline (70%).
Median duration of HPV persistence—Including all estimates (N=119), regardless of
HPV type or group, the average median duration of any-HPV was 9.8 months (Figure 1).
There were 15 independent study results for estimation of median duration of any-HPV,
which had the widest range estimated median durations, from 6.0 to 24.0 months. Weighted
average median duration for any-HPV infection was 9.8 months. HR-HPV (n=15) had a
slightly longer median duration at 9.3 months (range: 6.0–14.8) compared to LR-HPV
(n=11) at 8.4 months (range: 4.3–13.3). Among the individual HPV-types, median duration
was longest for HPV-31, with a weighted average of 14.4 months, followed by HPV-33 at
12.5 months, and HPV-16 at 12.4 months. Median duration of detection of all other high-
risk HPV types ranged from 6.0 to 11.7 months. The median durations of any-HPV and HR-
HPV from populations of women with 100% normal cytology at baseline were 11.5 and
10.9 months, respectively.
Time-specific HPV persistence—Forty-seven articles reported at least one estimate of
HPV persistence at a standard 6 month interval for any-HPV (n=20), HR-HPV (n=22), LR-
HPV (n=7), HPV-16 (n=16) (Figure 2). The thick gray curve in each panel represents the
weighted summary of all study estimates across time. The curves for any-HPV and LR-HPV
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were similar, with a rapid decrease in persistence within 6 months, followed by a slow
decline through 36 months. There was a relatively slower, more uniform decrease in HR-
HPV and HPV-16 persistence over time. Between studies, the variability in estimates
differed by HPV type and by time. At 6 months, estimates of the proportion persistent
ranged from 16–88% for any-HPV, 18–90% for HR-HPV, and 50–100% for HPV-16. At 12
months, the proportion persistent ranged from 10–68% for any-HPV, 24–63% for HR-HPV,
and 0–97% for HPV-16.
Age-specific HPV persistence—Articles that presented estimates of persistence
stratified by age were limited (n=14) (Figure 3). Estimates of any-HPV by age were most
common (n=8), followed by HR-HPV estimates (n=5). Three of the HPV persistence results
were based on incident infections30–32. There was no distinguishable trend of HPV
persistence by age. The study with the shortest persistence follow-up (3 months)33 found
that women aged <25 years were more likely to persist compared to all older age groups.
Three other studies found a similar trend: older women had lower persistence compared to
younger women34–36. However, the study with the longest persistence follow-up (67
months)37 found the opposite result: younger women had a lower proportion of persistent
infections compared to older women, as did four other studies30, 38–40.
Analytic results
Evaluation of study characteristics and persistence definitions—Of the 86
included articles, 4 did not report proportion persistent results (these estimated median
duration of infection in Figure 1), thus the number of estimates included in each meta-
regression could be more or less than 82 depending on whether estimates from the same
study population entered into different study characteristic strata. After applying the
inclusion and selection rules, 68 independent estimates produced a summary estimate for
persistence at 6 month of 39% (95% confidence interval (CI): 34%, 45%).
The p-value for Cochran’s Q statistic was less than 0.01 for all meta-analyses, indicating a
large amount of variation among the proportion persistent estimates included in each meta-
regression. Given the relatively small number of studies in each meta-regression stratum and
the inclusion of several variables in each model, most meta-regression coefficient estimates
were imprecise, as indicated by relatively wide confidence intervals. Compared to Europe,
which had the highest proportion persistence at 6 months (49%; 95% CI: 40%, 57%), HPV
persistence at 6 months was significantly lower among studies from North America (40%;
95% CI: 31%, 48%) and from Central and South America (28%; 95% CI: 8%, 48%) (Table
2). There was a slight difference in persistence between younger (<30) and older women
(≥30) at 40% (95% CI: 32%, 48%) and 48% (95% CI: 41%, 535), respectively. HPV
persistence was highest among the few studies that used pU1M/pU2M, L1C1/L1C2, GP5/6
or other L1 primers (56%; 95% CI: 40%, 72%) and Hybrid Capture 1/2 (46%; 95% CI:
36%, 55%).
In comparison to the summary estimate for any-HPV persistence at 6 months (43%; 95% CI:
37%, 48%), HR-HPV persistence was nearly identical (0.5%; 95% CI: −7%, 8%), whereas
LR-HPV persistence was lower (−10%; 95% CI: −20%, – 0.1%). HPV-16 (54%; 95% CI:
48%, 60%), HPV-18 (48%; 95% CI: 40%, 56%) and HPV-33 (47%; 95% CI: 35%, 59%)
had the highest proportion persistent. HPV-51 (30%; 95% CI: 19%, 42%) and HPV-66
(29%; 95% CI: 16%, 43%) had the lowest proportion of persistent infections at 6 months.
Consistent with the trend observed in Figure 1, HPV-16 persistence (54%; 95% CI: 48%,
60%) was slightly higher than HPV-18 (48%; 95% CI: 40%, 56%).
There was a slight difference in the proportion HPV persistent when persistence was defined
by a minimum of two time points (43%; 95% CI: 37%, 49%) compared to a minimum of
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three time points (50%; 95% CI: 36%, 63%). There was also a slight increase in the
proportion HPV persistent as the minimum duration of infection required to be considered
persistent increased from 6 months or less (44%; 95% CI: 35%, 53%) compared to 12
months or more (52%95% CI: 41%, 62%). There was little difference between the summary
estimates for HPV type-specificity: non-type-specific persistence was 44% (95% CI: 36%,
51%) and type-specific persistence was 43% (95% CI: 36%, 50%). Similarly, there was little
difference in estimates of persistence by baseline HPV status: 45% (95% CI: 33%, 57%) for
incident infections and 43% (95% CI: 36%, 49%) for infections that were prevalent at
baseline.
DISCUSSION
This systematic literature review and meta-analysis of HPV persistence combined data on
over 100,000 women from 86 studies to examine study characteristics that might affect the
duration and likelihood of persistent HPV infection. We found that the median duration of
HPV detection was slightly less than one year overall and among women with normal
cytology. Given these findings, repeat HPV testing after one year follow-up is expected to
have substantial utility for cervical cancer screening. Although most studies were similar in
that they defined HPV persistence as HPV positivity at two or more time points (73%), not
all required the same HPV type to be detected at consecutive visits (42% non-type-specific
persistence). The proportion persistent at 6 months varied across studies and the
heterogeneity in the estimates was largely a function of HPV type. The most persistent types
were HPV-16, 31, 33 and 52 in the analysis of median duration, which were notably higher
than the least persistent types HPV-35, 51, 66 and 68.
The median duration of any-HPV detection was approximately 10 months, whereas the
duration of HR-HPV detection was slightly shorter, and that of LR-HPV infections even
shorter. This pattern was consistent with the results from the meta-regression of HPV type.
Previous reports comparing the duration of HPV-16 infection and HPV-18 infection have
been inconsistent41–44, which is confirmed by the variability in our results. Assuming that
heterogeneous results can be combined, the estimated average median duration of HPV-16
detection in this systematic review was 12.4 months, compared to 9.8 months for HPV-18.
Meta-regression revealed a similar pattern, where the proportion persistent for HPV-18 was
9% less than that for HPV-16 at 6 months. Among alpha-9 (genotypes (HPV-16, 31, 33, 35,
52, 58)45, HPV-16, 31, 33 and 52 were the most persistent. Among alpha-7 genotypes
(HPV-18, 39, 45, 59, 68, 70)45, HPV-18, 39, 45, and 59 were the most persistent. Given the
biological importance of persistent HPV infections in HPV-related invasive cervical cancer,
the relatively longer persistence for HPV-31, 33 and HPV-52 infections supports their
inclusion in next generation prophylactic HPV vaccines.
Although the observed patterns of HPV persistence were generally similar between the
analyses of median duration and the proportion persistent, discrepancies in the absolute
values were noted. For example, we found that the median duration of HR-HPV persistence,
the time at which 50% of women had persistently detectable HR-HPV infections, was on
average 9.8 months (N=15), whereas meta-regression indicated that 38% persisted at 6
months (N=41). The studies included in the two analyses differed; however, such
discrepancies may also result from a potential underestimation of the proportion persistent in
meta-regression analysis. The variable we used in meta-regression to control for the time at
which persistence was measured corresponded to the interval between two study visits,
unless the mean or median time at which persistence was measured was reported, because
persistence is most commonly defined as two or more HPV positive visits. However, based
on this common definition of HPV persistence, a woman could actually have had more than
2 positive visits, leading to a potential underestimation of how long her HPV infection
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actually persisted. This would have affected estimates of the proportion persistent but not
estimates of median duration, which would take into account the exact number of HPV
positive study visits for each women over study follow-up. Also, an important point
regarding testing intervals is that if future studies aim to estimate persistence with the
highest degree of accuracy, for example down to the month, it would require sample
collection at a minimum of weekly intervals, whereas the current literature tests, on average,
every 6 months. Length of testing interval might also explain our observation of a higher
proportion of women with persistently detectable HPV infections in studies with intervals of
12 months or more as compared to 6 months or less; more frequent testing internals would
be expected to detect transient infections that may have been missed by testing with longer
intervals. Furthermore, we found that most studies did not take into account in the
definitions of persistence or clearance the potential for HPV latency46, and thus did not
permit the differentiation between true biological persistence and persistence as measured by
detectable HPV DNA at the mucosal surface.
Given the limited data available for specific age groups, it is difficult to make definitive
conclusions about the relation between age and HPV persistence. Although no distinct trend
by age was observed across studies that presented age-stratified estimates, the proportion of
women with persistently detectable HPV infections was slightly higher in meta-regression
analysis among study populations with a mean age of 30 years and older compared to those
with a mean age under 30. These data reflect the inconsistent results reported in the
literature and suggest that the complex relationship between age and persistence is likely
mediated by additional factors such as incident/prevalent infection status, study design,
differences in immune response, and population-level characteristics such as number and
type of recent and lifetime sexual partners. Recently, a large study found prevalent HPV
infections were slower to “clear” (i.e., become non-detectable) in older compared to younger
women, but no difference in persistence of incidence infections was reported by age47. Our
descriptive figure was predominately comprised of prevalent HPV infections; thus, we were
unable to reliably compare persistence of prevalent versus incident infections by age. In
addition, although meta-regression did not identify differences between the proportion of
incident and prevalent infections that remained persistent, it is important to note that the
interpretation of these estimates are different. Prevalent infections are left-censored so true
persistence is likely greater than measured persistence, whereas persistence of incident
infections is estimated beginning from the first detection during the study.
HPV persistence within strata of individual study characteristics showed notable
heterogeneity, potential evidence that the use of broad or heterogeneous categories may
mask important associations between study variables. This complexity is not unexpected
given that persistence estimates within a stratum may differ by several other characteristics
including study region, HPV type, testing interval, or detection method. For example, each
HPV detection assay has different sensitivities for the detection of individual HPV types,
especially if multiple HPV types are present48, 49. In addition, previous studies suggest that
most women with persistent HPV infections actually have type-specific infections even if
non-type-specific persistence was measured50, which may explain why we observed no
difference between type-specific and non-type-specific HPV persistence. Although it is
likely that the relation between such study characteristics and HPV persistence are multi-
factorial, data were too sparse to examine several study characteristics simultaneously.
Future reviews could consider obtaining individual-level study data for a pooled analysis
approach.
This meta-analysis systematically described the patterns and characteristics associated with
the persistence and duration of HPV infections in published studies. Our results confirm
individual study findings that specific HPV types, particularly HPV-16, are more likely to
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produce persistent infections with a longer duration of detection than other HR-HPV types.
Repeat and possibly type-specific HPV testing would increase specificity over a one-time
HPV test, thus improving clinical detection of cervical high-grade precancer by providing a
higher sensitivity and similar specificity as compared to cytologic screening5. Current ASC/
ASCCP/ASCP guidelines recommend a one-year repeat screening interval for women over
30 years who are HPV-positive with normal cytology. These guidelines are consistent with
our systematic review, which indicates that the median duration of HPV detection was less
than one year among women with normal cytology for both any-HPV and high-risk type
infections.
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HPV persistence varied notably across studies and was largely mediated by study region,
detection method, and HPV type. We estimated that approximately half of HPV
infections persist past 6–12 months. Weighted median duration of any-HPV detection
was 9.8 months and HR-HPV was 9.3 months. Repeat HPV testing at 12 month intervals
could identify women at increased risk of high-grade cervical precancer due to persistent
HPV infections.
Rositch et al. Page 17













Rositch et al. Page 18














Forest Plots of the Median Duration of Infection by Human Papillomavirus Group or Type.
Estimates are for human papillomavirus infections prevalent at baseline unless otherwise
indicated, where * denotes incident infections and † denotes a mixture of prevalent and
incident infections. The vertical line represents the overall, weighted median of 9.8 months.
Rositch et al. Page 19













Rositch et al. Page 20













Rositch et al. Page 21













Rositch et al. Page 22














Estimates of the Proportion of Infections Persisting across Time for A) any-HPV, B) high-
risk HPV, C) low-risk HPV, D) HPV type 16. The legend in each panel provides the
references for articles that contributed data to each figure. The thick gray curve is a locally
weighted polynomial regression (lowess) estimate based on data from all studies over all
time points.
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Age-Specific HPV Persistence. Estimates of the proportion of women with persistent human
papillomavirus (HPV) infection by time are presented for any-HPV (squares) or high-risk
HPV (circles). All results were based on prevalent infections unless otherwise noted, where*
indicates HPV persistence based on incident infections. Some points were dithered slightly
to avoid overlap.
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Table 1
Characteristics of Human Papillomavirus (HPV) Persistence Studies and Results from Published Studies






  Europe 34 39.5 24, 27–29, 34, 36, 39, 43, 51–76
  North America 25 29.1 21–23, 26, 33, 35, 38, 41, 42, 77–92
  Central/South America 17 19.8 20, 25, 30–32, 37, 44, 93–102
  Africa, Asia, Australiaa 8 9.3 40, 103–109
  Multicenterb 2 2.3 110, 111
Mean age of women
  < 30.0 years 33 38.4 23, 24, 27, 28, 30, 33–39, 41–44, 51, 57, 58, 62, 63, 67, 70, 78, 80, 82, 83, 86, 89, 98, 106, 110, 111
  ≥ 30.0 years 50 58.1 20, 21, 25, 26, 29–40, 53–57, 59–61, 64–66, 68, 69, 71–76, 79, 87, 90–93, 96, 99, 101–104, 107, 108, 112
  Not stated 12 14.0 22, 52, 81, 84, 85, 88, 94, 95, 97, 100, 105, 109
Baseline abnormal cytologyc
  0% abnormal 56 65.1 21, 23, 24, 26–31, 33, 34, 36, 38–40, 42–44, 51, 52, 54–61, 63, 65–71, 73–76, 78, 79, 81, 82, 84, 88–91, 93, 94, 104, 105, 107, 110, 111
  1–15% abnormal 8 9.3 53, 59, 62, 65, 77, 83, 106, 109
  Not stated 24 27.9 20, 22, 25, 32, 35, 37, 41, 64, 72, 80, 85–87, 92, 95–103, 108
HPV DNA detection method
  MY09/11 ± other primers 37 43.0 20, 21, 23, 25, 26, 32, 33, 37, 38, 41, 42, 51, 53, 61, 62, 73, 78, 79, 81, 82, 85, 87–91, 96–103, 108, 109, 112
  SPF10, PGMY09/11, GP5+/6+ 19 22.1 30, 31, 39, 40, 43, 44, 54, 57, 58, 64, 65, 67–69, 75, 80, 86, 110, 111
  pU1M/pU2R, L1C1/L1C2,
GP5/6 ± type-specific, other L1
primers 7 8.1
27, 36, 66, 71, 95, 105, 106
  Type-specific primers 10 11.6 22, 24, 28, 39, 52, 72, 83, 84, 92, 104
  Hybrid Capture 1/ 2 14 16.3 29, 34, 35, 55, 56, 59, 60, 63, 70, 74, 76, 93, 94, 107
HPV typed
  Any-HPV 49 57.0 20–23, 25–27, 30, 32, 33, 37–44, 53, 56, 57, 61, 62, 67, 72, 73, 75, 80–82, 84, 86, 87, 89–92, 96–103, 106, 108, 109, 112
  HR-HPV 56 65.1 20, 23–25, 29–38, 40, 41, 44, 51, 54–60, 63–65, 67–70, 73–76, 79, 80, 82, 85–87, 91–95, 99–102, 104, 106, 107, 110, 111
  HPV-16 39 45.3 20, 22, 24, 25, 28, 30–33, 37–44, 52, 54, 57, 58, 66, 71, 72, 78, 80, 83, 84, 88, 89, 91, 95, 96, 100, 105, 106, 108, 110, 112
  HPV-18 26 30.2 20, 22, 25, 30–33, 39–43, 54, 57, 58, 72, 80, 82, 84, 89, 91, 100, 106, 108, 110, 112
  LR-HPV 20 23.3 20, 23, 25, 30–32, 37, 38, 40, 41, 44, 56, 57, 80, 82, 86, 87, 91, 101, 102
HPV persistence definitione
  ≥2 positive visits 63 73.3 20, 23–29, 33, 34, 36–39, 41, 51, 55–62, 64–67, 69, 70, 72–76, 78, 80–85, 87–90, 92–94, 96–101, 103, 104, 106, 109–112
  ≥3 positive visits 12 14.0 36, 42, 52, 56, 71, 79, 83, 97, 99, 105, 111
  Clearance or duration 19 22.1 22, 30, 31, 35, 40–44, 53, 54, 63, 68, 86, 91, 93, 95, 108, 112
  Persistent pairs 2 2.3 21, 102
Minimum HPV persistence
duration
  < 6 months 27 31.4 20, 23, 25, 28, 32–34, 55, 56, 60, 64, 68, 74, 78, 80, 83, 86, 87, 89, 91, 98, 99, 101, 102, 104, 107, 108
  6 to <12 months 38 44.2 21, 22, 27, 30, 31, 34–38, 40–42, 44, 51, 53, 54, 59, 62, 67, 70–72, 75, 82–85, 90, 92, 94, 95, 99, 105, 109–112


















  ≥12 months 27 31.4 24, 26, 29, 34, 36, 38, 39, 52, 56–58, 61, 63, 65, 66, 69, 73, 76, 79, 81, 93, 97, 99, 100, 103, 106, 111
  Not stated 3 3.5 43, 88, 96
Mean testing interval
  < 6 months 20 23.3 20, 25, 28, 32, 33, 56, 68, 78, 80, 83, 86, 89, 91, 99, 101, 102, 104, 105, 107, 108
  6 to <12 months 35 40.7 21–23, 27, 30, 31, 34, 38, 40–44, 51, 54, 59, 60, 64, 70–72, 74, 75, 79, 84, 85, 87, 90, 94, 95, 98, 109–112
  ≥12 months 30 34.9 24, 26, 29, 35–37, 39, 52, 53, 55, 57, 58, 61–63, 65–67, 69, 73, 76, 81, 82, 88, 92, 93, 97, 100, 103, 106
  Not stated 1 1.2 96
Type-specific HPV persistence
  Type-specific 62 72.1 20–25, 27, 28, 30–33, 37–44, 51, 52, 54, 57, 58, 61, 62, 64, 66–69, 71–73, 78–80, 82–89, 91, 92, 95–98, 100–102, 105, 106, 108, 110–112
  Non-type-specific 36 41.9 24, 26, 29, 34–36, 38–40, 53, 55–57, 59, 60, 63, 65, 67, 70, 73–76, 81, 90, 93, 94, 98, 99, 101, 103, 104, 106, 107, 109, 112
Baseline HPV infection status
  Prevalent 60 69.8 23, 27–29, 32–41, 44, 53–71, 73–76, 81, 82, 84, 86–88, 90, 92–97, 100, 101, 103–109
  Mixed prevalent and incident 13 15.1 22, 23, 28, 30, 34, 41–43, 78, 83, 89, 90, 110
  Incident 19 22.1 20, 21, 26, 28, 31, 32, 51, 52, 72, 79, 80, 85, 90, 91, 98, 99, 102, 111, 112
  Not stated 2 2.3 24, 25
HPV: human papillomavirus; LR: Low-risk; HR: High-risk
a
Africa106, 108, 109, Asia40, 104, 105, 107, Australia103
b
Multicenter: North/South/Central America110, 111 Australia, Belgium, Brazil, Canada, Finland, Germany, Italy, Mexico, Philippines, Spain,
Taiwan, Thailand, UK, and USA
c
Classification based on individual study definitions of abnormal cytology but generally included ASCUS or greater
d
Any-HPV: any and all HPV types detected; HR-HPV: HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68; LR-HPV: all other genital
HPV types.
e
Persistent pairs: any pair of two consecutive positive visits (v, v+1)
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